BridgeBio Pharma (NASDAQ:BBIO) Director Sells $150,579.72 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Hannah Valantine sold 2,196 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $68.57, for a total value of $150,579.72. Following the completion of the sale, the director owned 9,259 shares in the company, valued at $634,889.63. This represents a 19.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hannah Valantine also recently made the following trade(s):

• On Monday, June 22nd, Hannah Valantine sold 2,808 shares of BridgeBio Pharma stock. The shares were sold at an average price of $68.00, for a total value of $190,944.00.

BridgeBio Pharma Stock Up 0.9%

NASDAQ BBIO traded up $0.63 during trading on Wednesday, hitting $69.26. The stock had a trading volume of 4,190,473 shares, compared to its average volume of 2,788,713. The company has a market capitalization of $13.56 billion, a PE ratio of -18.52 and a beta of 0.97. The firm has a 50 day moving average price of $69.37 and a 200 day moving average price of $71.90. BridgeBio Pharma, Inc. has a twelve month low of $41.80 and a twelve month high of $84.94.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The firm had revenue of $194.51 million for the quarter, compared to analyst estimates of $178.07 million. During the same quarter in the previous year, the company earned ($0.88) earnings per share. The business’s quarterly revenue was up 66.8% on a year-over-year basis. On average, sell-side analysts anticipate that BridgeBio Pharma, Inc. will post -2.29 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have commented on BBIO shares. Truist Financial boosted their price target on shares of BridgeBio Pharma from $95.00 to $102.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Weiss Ratings reissued a “sell (d)” rating on shares of BridgeBio Pharma in a research note on Friday, May 15th. Royal Bank Of Canada initiated coverage on BridgeBio Pharma in a research report on Thursday, April 9th. They issued an “outperform” rating and a $100.00 price target on the stock. JPMorgan Chase & Co. boosted their price objective on BridgeBio Pharma from $89.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 10th. Finally, Canaccord Genuity Group started coverage on shares of BridgeBio Pharma in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $104.00 price target for the company. Twenty-two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.05.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Aster Capital Management DIFC Ltd purchased a new position in shares of BridgeBio Pharma in the 3rd quarter valued at about $31,000. Harvest Fund Management Co. Ltd purchased a new stake in BridgeBio Pharma during the third quarter worth approximately $34,000. Jones Financial Companies Lllp acquired a new position in BridgeBio Pharma in the first quarter valued at approximately $35,000. Huntington National Bank boosted its holdings in BridgeBio Pharma by 111.7% in the third quarter. Huntington National Bank now owns 743 shares of the company’s stock valued at $39,000 after purchasing an additional 392 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its stake in BridgeBio Pharma by 91.4% in the fourth quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock valued at $39,000 after purchasing an additional 245 shares during the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.